0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Erythropoietin Levels and Androgens Use: What Is Their Relationship in the Correction of Anemia?

Charles J. Diskin, MD
Arch Intern Med. 2007;167(3):309. doi:10.1001/archinte.167.3.309.
Text Size: A A A
Published online

Extract

While Daniell1 writes that androgen therapy is a proven treatment of anemia in patients with end-stage renal disease (ESRD) through the stimulation of endogenous erythropoietin levels or some other erythropoietic cells, Spivak2 notes in his reply that such an assertion contradicts the known physiology of erythropoiesis. Perhaps I can help resolve some of the conflict. Thirty years ago when we used androgens in the treatment of ESRD, we had just begun to realize that the kidney participated in erythrocyte regulation. At that time, we used a mouse bioassay for detecting the functional presence of erythropoietin, but it could not distinguish between the absence of erythropoietin and the lack of its efficacy due to inhibiters. We then developed an enzyme-linked immunosorbent assay to detect the actual quantities of erythropoietin in patients with ESRD and found that they had higher erythropoietin levels than our control patients and that those levels seemed to be independent of androgen use, transfusion dependency, and hematocrit level (Figure).3 Like Daniell,1 we even postulated at that time that androgens might act by a separate mechanism from erythropoietin. Because the development of biorecombinant erythropoietin was still many years away, we had not yet learned that there were factors such as age, hyperparathyroidism, inflammation, inadequate dialysis, angiotensin antagonists, acidosis, and hyperphosphatemia4 that can produce erythropoietin resistance and distort such relationships as we had chosen to observe. Spivak2 is correct that androgens are neither necessary nor sufficient in the correction of anemia. Since the introduction of biorecombinant erythropoietin, most of the anemia in ESRD is corrected, regardless of endogenous erythropoietin levels. Such a feat was almost never accomplished with androgen therapy before the introduction of biorecombinant erythropoietin, as noted in the Figure. Endogenous erythropoietin levels in ESRD do not seem to predict hematocrit levels or a response to biorecombinant erythropoietin. Recently, we found that increased age alone, unrelated to sex, is associated with resistance to biorecombinant erythropoietin,4 which could explain the association that Daniell1 notes in his figure and has mistakenly attributed to the effect of diminishing endogenous androgens in elderly men. The National Kidney Foundation does not recommend androgens as an adjunctive therapy for erythropoietin resistance because the adverse effects of androgen therapy appear to outweigh its potential benefits. Therefore, investigation of reversal of inhibiters of erythropoietin, such as cytokines like tumor necrosis factor α and defensins like hepcidin, may be a more fruitful pathway in the treatment of erythropoietin resistance.5

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.

A, Effect of androgens; B, erythropoietin level vs hematocrit level.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999;14 Suppl 2():50-60.
Jobs
brightcove.createExperiences();